Sanofi opens new R&D hub in Shanghai
This article was originally published in Scrip
Sanofi is bucking a trend in China. While many foreign companies have slowed down their investment plans there because of the country's recent nationwide anti-corruption and anti-monopoly campaigns as well as increasingly tightening compliance policies that affected major multinationals including GlaxoSmithKline and Eli Lilly, Sanofi did exactly the opposite.
You may also be interested in...
The road to China's health-care market, once seen to be paved with gold by many medtech companies, is presenting more obstacles than before as a result of increased local competition and challenging policies. Multinationals and start-ups attending the recent China Healthcare Investment Conference discussed ways in which the medtech industry could continue to capitalize on this market's potential.
China is pushing ahead with initiatives in the precision medicine area, where it sees targeted diagnosis and treatment as particularly valuable in areas such as oncology, diabetes and cardiovascular disorders.
The China Food and Drug Administration has released the final version of its biosimilars guideline1.